Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors
I'm PortAI, I can summarize articles.
Biogen Inc.'s stock fell 2.41% to $171.50 on Tuesday, underperforming compared to competitors like Johnson & Johnson, Pfizer, and AbbVie. The stock's decline ended a two-day winning streak and was part of a broader market downturn, with the S&P 500 and Dow Jones also falling. Biogen's trading volume exceeded its 50-day average, and the stock remains 7.38% below its 52-week high.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Dow Jones The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments